Introduction: There is an increasing incidence and prevalence of patients with chronic kidney disease requiring replacement therapy, with poor outcomes and a high cost. Pre-dialysis programs allow the delay in the evolution of renal disease and reduction of cardiovascular events.
Objective: To assess the benefit of a pre-dialysis program in patients with Stage IV CKD, assisted at RTS renal unit in Manizales, Colombia.
Materials and methods: Retrospective cohort study. It was a complete database of clinical and paraclinical variables of the selected patients from the year of admission for three years. Statistical analysis was made with SPSS 12.0 software. Measures of central tendency (mean), of position (percentiles) and of dispersion (standard deviation, range) were used for the variables of a quantitative nature. The proportions for the variables of a qualitative nature were calculated.
Results: Control of systolic and diastolic blood pressure in the 3 and 2 years of monitoring, respectively, was statistically significant. Significance was observed during the monitoring of ferritin in the first and second years. In addition, there was a stable control of hemoglobin during the period of observation with minimal need for erythropoietin (23.07%). No patient initiated dialysis during the monitoring period.
Conclusion: A pre-dialysis program ensures greater adherence and control of targets in clinical and paraclinical variables in patients with chronic kidney disease.
2. Pablo Amair, Patrick Wagner. Guías para el cuidado del paciente con insuficiencia renal crónica en etapa de prediálisis. Disponible en: http://www.readbag.com/awgla-publicaciones-descargas-guias-para-el-cuidado.
3. Ayman Karkar. The value of Pre- Dialysis care. Saudi J Kidney Dis Transpl 2011;22(3):419-427.
4. Ratcliff J, Phillips RE, Oliver DO. Late referral for maintenance dialysis. Br Med J 1984;288:441-3.
5. Moniek CM de Goeij, Nora Voormolen, Nynke Halbesma, Dinanda J de Jager, Elisabeth W Boeschoten, Yvo WJ Sijpkens, et al, for the PREPARE-1 study group. Association of blood pressure with decline in renal function and time until the start of renal replacement therapy in pre-dialysis patients: a cohort study. BMC Nephrology 2011;12:38.
6. Eighth Joint National Committee (JNC 8) JAMA 2014;311:507-520.
7. National Kidney Foundation: K/DOQI clinical practice guidelines in chronic kidney disease. Kidney Int 2013;83:377-383.
8. KHA-CARI Guideline. Cardiovascular disease in patients with chronic kidney disease. Nephrology 2014;19:3-10
9. Remuzzi G, Bertani T: Pathophysiology of progressive nephropathies. NEngl J Med 1998;339:1448-1456.
10. Nobuharu Fujiwara, Tsukasa Nakamura, Eiichi Sato, Yasuhiro Kawagoe, Yutaka Hikichi, Yoshihiko Uedad, et al. Renovascular Protective Effects of Erythropoietin in Patients with Chronic Kidney Disease. Intern Med 2011;50:1929-1934.
11. Srisawat N, Manotham K, Eiam-Ong S, Katavetin P, Praditpornsilpa K, Eiam-Ong S. Erythropoietin and its non-erythropoietic derivative: Do they ameliorate renal tubule interstitial injury in ureteral obstruction? Int J Urol2008;15:1011-1017.
12. Wajeh Qunibi, Wolfgang C Winkelmayer, Richard Solomon, Moustafa Moustafa, Paul Kessler, Chiang-Hong Ho, et al. A randomized, double-blind, placebo-controlled trial of calcium acetate on serum phosphorus concentrations in patients with advanced nondialysis- dependent chronic kidney disease. BMC Nephrology 2011,12:9.
13. National Kidney Foundation: K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003;42(suppl):1-201.
14. Isakova T, Gutiérrez OM, Chang Y, Shah A, Tamez H, Smith K, et al. Phosphorus Binders and Survival on Hemodialysis. J Am Soc Nephrol 2009;20:388-396.